Omega 3 versus Omega 6 polyunsaturated fatty acids in cardio-metabolic health

Halim, M and Halim, A
10.36502/2020/hcr.6166

| Title          | Omega 3 versus Omega 6 polyunsaturated fatty acids in cardio-metabolic health |
|---------------|--------------------------------------------------------------------------------|
| Authors       | Halim, M and Halim, A                                                          |
| Type          | Article                                                                        |
| URL           | This version is available at: http://usir.salford.ac.uk/id/eprint/57516/        |
| Published Date| 2020                                                                           |

USIR is a digital collection of the research output of the University of Salford. Where copyright permits, full text material held in the repository is made freely available online and can be read, downloaded and copied for non-commercial private study or research purposes. Please check the manuscript for any further copyright restrictions.

For more information, including our policy and submission procedure, please contact the Repository Team at: usir@salford.ac.uk.
Omega 3 versus Omega 6 Polyunsaturated Fatty Acids in Cardio-Metabolic Health

Halim M¹, Halim A²

¹University of Salford, MSc Biomedical Science, Greater Manchester, United Kingdom
²Zhong Shan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Corresponding Author: Michael Halim

Address: University of Salford, MSc Biomedical Science, Greater Manchester, United Kingdom; Email: michaelhalim1000@gmail.com

Received date: 22 May 2020; Accepted date: 18 June 2020; Published date: 27 June 2020

Citation: Halim M, Halim A. Omega 3 versus Omega 6 Polyunsaturated Fatty Acids in Cardio-Metabolic Health. J Health Care and Research. 2020 Jun 27;1(2):83-100.

Copyright © 2020 Halim M, Halim A. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Cardiometabolic diseases like type 2 diabetes, metabolic syndrome, heart failure, and other cardiovascular complications are the leading cause of mortality and morbidity across the globe. These conditions are directly attributed to modifiable behaviors such as sedentary activity, poor diet, excessive consumption of alcohol, or smoking. Efforts aimed towards their prevention and management are, therefore, not only essential in the accomplishment of the healthy populations but also for eliminating the associated cost and health burdens. Dietary change is an important approach to the promotion of cardiometabolic health. Omega 3 (C20–22 ω 3) polyunsaturated fatty acids have pleiotropic effects on the functioning of cells, control inflammatory factors, and cellular events in vascular endothelial cells and cardiomyocytes. The hypolipemic, anti-arrhythmic, and anti-inflammatory properties of fatty acids offer cardioprotection. Government agencies and national heart associations recommend increased consumption of omega 3 polyunsaturated fatty acids (PUFA) supplements and fish to prevent cardiometabolic diseases.

Purpose of the Study: The purpose of this study is to investigate the role played by ω-3 and ω-6 polyunsaturated fatty acids in promoting cardiometabolic health.

Methods: The research study searched databases such as MEDLINE®, Embase, PsycINFO, CINAHL® and the Cochrane Library for relevant research studies evaluating the function/benefits of polyunsaturated fatty acids particularly ω-3 and ω-6 polyunsaturated fatty acids in promoting cardiometabolic functions published between 2011 and 2020. A total of 77 research studies were identified and used in the meta-analysis.

Results: Results from the meta-analysis indicated that polyunsaturated fatty acids lower the risk for cardiovascular disease by limiting inflammation of blood vessels, reducing thrombosis, increasing levels of high-density lipoproteins, reducing levels of low-density lipoproteins, and reducing risk factors associated with hypertension.

Conclusion: Given the benefits of polyunsaturated fatty acids lower the risk for cardiovascular diseases indicated in the meta-analysis. Therefore, human diets must contain the required amounts of PUFA due to the associated benefits.

Keywords

Omega-3, Omega-6, Polyunsaturated fatty acids, Cardiometabolic health
Background
Cardiometabolic Syndrome is a combination of metabolic dysfunctions characterized by impaired glucose tolerance, insulin resistance, hypertension, dyslipidemia, and central adiposity [1]. Cardiometabolic health encompasses metabolic and cardiovascular diseases [2]. Examples of cardiovascular diseases include heart failure, heart attack, and cardiomyopathy, among others, while metabolic complications include type 2 diabetes and metabolic syndrome [3]. According to [4], cardiometabolic diseases pose significant health and economic burden to the world with high prevalence rates expected. Other factors that predispose individuals to cardiometabolic diseases include a poor diet, sedentary lifestyle, short sleep duration, and prolonged sitting that are significant elements of the modern lifestyles [5]. Cardiometabolic diseases share risk factors, as evident in the impact of obesity/overweight and elevated blood pressure that can be modified through lifestyle choices and proper diet [6]. PUFAs are fatty acids containing more than one double bond in their chain with examples including omega-3 (ω-3), omega-6 (ω-6), and omega-9 (ω-9) fats [7]. PUFAs can be easily obtained from various food products to enhance cardiometabolic health. This article reports the impact of omega-3 and omega-6 PUFAs in the promotion of cardiometabolic health.

Methods
Database Searches:
The research study employed systematic meta-analysis to analyze different research studies. Concerning this, a systematic computerized literature search of EMBASE, PubMed, PsycINFO, MEDLINE, as well as CINAHL databases was performed for different research studies published in English up to February 2020. Generally, the search was conducted by combining a number of keywords as well as medical subheadings; furthermore, no limitations with regard to the search strategy were inserted. Some of the keywords used in the searches included: Omega-3, Omega-6, Polyunsaturated fatty acids, cardiometabolic health. On the other hand, some of the medical subheadings included cardiometabolic health benefits of Omega-3 and Omega-6, respectively. References from all the relevant literature were carefully hand searched from these databases and also used to identify additional relevant research studies. Following the initial search, a total of 151 relevant articles were located.

Article Screening Methods:
Literature search yields hundreds to thousands of candidate documents where most of them get excluded after screening because they are not relevant to the topic under study. Screening candidate articles in a systematic review for inclusion takes much time when conducted manually [8]. Automated tools dedicated to screening candidate studies were employed to reduce human effort and to arrive at the main objective within a shorter period. The methods used are based on supervised machine learning techniques. Based on trained models, they were able to identify relevant keywords in the abstract of candidate articles. Keywords used here included omega 3, omega 6, cardiometabolic diseases, polyunsaturated fatty acids, and PUFA. Articles screened were elected from those which were published between 2010 and 2020 to help obtain the latest and most relevant information. The screening exercise yielded to 114 articles that were relevant to this topic and had the latest information about the contribution of omega 3 and 6 to cardiometabolic diseases. The screening method excluded those studies which did not meet a predefined set of characteristics. The results obtained were compared to the actual reviews inclusion list. The screening threshold rule used identified studies that met mentioned Polyunsaturated fatty acids (PUFAs) and Cardiometabolic health in the study abstract. This rule excluded 91.6% of studies retrieved.

Inclusion and Exclusion Criteria:
An exclusion/inclusion criterion used ensured that the selection of studies was unbiased and that the article selected focused on the main research question. An exclusion/ inclusion criterion was employed to first screen abstracts and titles related to cardiometabolic diseases, omega 3, and omega 6 polyunsaturated fatty acids. The next full text was retrieved from these articles and screened to determine whether the content fits the eligibility criteria of this task. Covidence, which is an online systemic review management tool, was
employed to offer independent abstract/title screening, data extraction, full-text screening, and risk of bias assessment. To selected quality sources, the criteria, thus, for the inclusion of research articles were as follows: the research study had to evaluate the function/benefits of polyunsaturated fatty acids, particularly ω-3 and ω-6 polyunsaturated fatty acids in promoting cardiometabolic functions. The second criteria are that the research had to be published between 2010 and 2020 to ensure relevancy. The third criterion that the research studies had to focus on human beings as opposed to animal studies. However, there were no limitations on the type of research paper included in the research study. After exclusion, a total of 20 high-quality research studies were acquired to be used in the research study, while 56 low-quality research studies were excluded.

Results

Crowe-White et al. (2018) reported that different fatty acids have varying effects on cardiometabolic health [9]. For instance, the ratios of ω-3 to ω-6 is not only essential in the production of eicosanoid metabolites that influence the inflammatory and homeostatic responses but also critical in the pathogenesis of diseases like diabetes [10,11]. The imbalances between the intake of ω-3 and ω-6 may lead to the imbalances in gene-nutrient interactions and endogenous mediators that may lead to biological consequences that influence the disease risk [12,13]. Other studies by [14,15] emphasized the need for replacing saturated fats with unsaturated fats as part of dietary controls towards the management of cardiovascular diseases. Similarly, [9] asserted that the intake of ω-3 and ω-6 PUFAs is beneficial for lowering the risks for cardiometabolic conditions while [16] emphasized the important role played by the two fatty acids in the regulation of the platelet function and thrombosis.

The effect of using omega-3 and omega-6 has been illustrated in various studies. Mozaffarian (2009) examined the combined effect of various omega-3 fats such as EPA and DHA on multiple cardiovascular outcomes has also been revealed [15]. The results indicate the combined dose of EPA and DHA has an anti-arrhythmic effect for weeks, triglycerides lowering for months to a year, heart rate lowering effects for months, and antithrombotic activity for weeks as revealed in (Fig-1). Similarly, [17] reported that the average dose of 500mg of either EPA or DHA significantly reduce adverse cardiovascular outcomes, as revealed in (Fig-2).
Impact of ω-3 and ω-6 PUFAs in Inflammation and Cardiometabolic Health:

Inflammation is vital for people’s survival by providing protection against infection and injury [18]. However, excessive inflammation is a driver to some diseases like heart diseases, metabolic syndrome, arthritis, cancers, and Alzheimer’s [19]. The establishment of the link between inflammation and cardiometabolic diseases, therefore, requires the development of the pharmacological and therapeutic strategies that are intended at the reduction of the inflammatory processes [20]. Diet contributes to inflammation due to the impact of the various proinflammatory substances like the cytokines that influence the mechanisms contributing to the cardiometabolic diseases [21]. For instance, the atherogenesis mechanism that influences the development of acute cardiovascular events arises from inflammatory processes [22]. Omega-3 and omega-6 PUFAs are critical elements of diet intake that significantly influence the occurrence of inflammation in the body and hence influence the status of cardiometabolic health of the individuals [23,24].

Despite the similarities in the benefits of ω-3 and ω-6 PUFAs in cardiometabolic health, the two fatty acids are associated with certain differences [25]. For instance, while ω-3 fatty acids are known for their anti-inflammatory properties, a high intake of ω-6 PUFAs is associated with inflammation [26]. The intake of ω-3 fatty acids also reduces the production of molecules such as eicosanoids and cytokines that are linked to inflammation [27]. Esser et al. (2015) report that chronic inflammation is linked to cardiometabolic diseases and hence implying that increased intake of ω-6 PUFAs may lead contribute to a high risk of conditions like obesity, cardiovascular disease, metabolic syndrome, and type 2 diabetes [28]. However, the work of [29] dismisses the theory that ω-6 PUFAs do not contribute to the inflammation. On the same note, [30] asserts that there is conflicting evidence regarding whether ω-6 PUFAs are proinflammatory or inflammatory. The work of [25] further states that the consumption of more ω-3 fatty acids is associated with a decreased risk of metabolic syndrome as compared to the consumption of ω-6. High consumption of seed oils contains levels of linoleic acid, which have been indicated to reduce oxidative stress, inflammation, and endothelial dysfunction [31].

Dietary levels of linoleic acid have been implicated in increasing levels of cyclooxygenase 2, resulting in the production of proinflammatory cytokines from arachidonic acid [26]. This explains an increase in linoleic acid lowers levels of arachidonic acid by breaking down proinflammatory cytokines (Fig-3). An additional arachidonic independent pathway promotes...
or increases the production of oxidized linoleic acid metabolites as well as proinflammatory eicosanoids, which serve to activate NF-κB while at the same time increasing proinflammatory cytokines as well as chemokines [26,32]. In addition, the provision of linoleic acid among individuals at risk of being diagnosed with cardiovascular diseases reduced total cholesterol, triglycerides, body mass index, and systolic blood pressure after a 12 month follow up period, as seen in (Table-1).

Dietary levels of linoleic acid have been implicated in increasing levels of cyclooxygenase 2, resulting in the production of proinflammatory cytokines from arachidonic acid [26]. This explains which an increase in linoleic acid lowers levels of arachidonic acid by breaking down proinflammatory cytokines. An additional arachidonic independent pathway promotes or increases the production of oxidized linoleic acid metabolites as well as proinflammatory eicosanoids, which serve to activate NF-κB while at the same time increasing proinflammatory cytokines as well as chemokines [26,32]. In addition, the provision of linoleic acid among individuals at risk of being diagnosed with cardiovascular diseases reduced total cholesterol, triglycerides, body mass index, and systolic blood pressure after a 12 month follow up period, as seen in (Table-1).

Table-1: Clinical data on changes in cardiovascular outcomes after the provision of linoleic acid following a 12 month follow up. A reduction in the levels of total cholesterol and triglycerides is observed above [34]

|                          | Baseline | 12 months follow up | Statistical Significance |
|--------------------------|----------|---------------------|-------------------------|
|                          | Control  | Intervention        | Control                 | Intervention  | p-value   |
| Total cholesterol        | 282      | 281.3               | 266.5                   | 243.9         | <0.0001  |
| Triglycerides            | 185.9    | 189                 | 151.8                   | 136.5         | 0.06     |
| Body mass index          | 25.4     | 25.1                | 24.5                    | 24.3          | 0.26     |
| Systolic blood pressure  | 136.9    | 136.6               | 136.5                   | 136.4         | 0.49     |
| Diastolic blood pressure | 88.5     | 88.5                | 87.9                    | 87.5          | 0.38     |
A key mechanism that results in the down-regulation of the synthesis of proinflammatory cytokines such as interleukin 6, tumor necrosis factor-alpha and monocyte chemoattractant protein-1 occurs in the adipose tissue [34,35]. DHA and EPA bind to G-protein coupled receptors present in the adipocytes and macrophages, resulting in the activation as well as the internalization of β-arrestin-2, and the formation of a complex GPR120/β-arrestine-2 [27]. The complex dissociates to transforming growth factor-beta (TGF-β) activated kinase 1 binding protein 1 (TAB1), which has been implicated in inhibiting and downregulating the activity of nuclear factor kappa B (NF-kB) [36,37]. Incorporating DHA into the lipid membrane also disrupts the activity of toll-like receptor 4 and inhibits several essential pathways related to fatty acid synthesis [27,34,38]. In addition, the presence of DHA and EPA downregulates the activity of nicotinamide adenine dinucleotide phosphate oxidase, which is key to producing reactive oxygen species required in the signaling of TLR-4 [38]. The mechanism linking PUFAs to inflammation is revealed below in (Fig-4).

Impact of ω-3 and ω-6 PUFAs in Hypertension:
Recent studies reveal that maintaining low blood pressure even among individuals not diagnosed with hypertension is essential in reducing the incidences of cardiovascular diseases [39]. PUFAs regulate blood pressure through a number of different mechanisms, with the most common one is promoting the release of renin from the kidney [40]. Diets rich in omega-3 fatty acids have also been shown to suppress the activity of ACE (angiotensin converting enzyme) while at the same time suppressing the formation of angiotensin II which significantly improves the production of endothelial nitric oxide, a potent vasodilator while at the same time suppressing the action of Transforming Growth Factor-Beta [41,42]. The process by which PUFAs reduce the incidence of hypertension is revealed below in (Fig-5).
A meta-analysis carried out by [43] also assessed the efficacy of omega-3 supplementation on pre-eclampsia or hypertension. The meta-analysis revealed which compiled 14 different results indicated that the use of omega-3 fats had a protective effect on pre-eclampsia as indicated by the meta-analysis summary below (Fig-6).

| Subgroup                  | Study name     | Events / Total | Statistics for each study | Risk ratio and 95% CI |
|---------------------------|----------------|----------------|---------------------------|-----------------------|
|                          |                |                | Risk ratio | Lower limit | Upper limit | p-Value | Relative weight |                |
| High risk pregnancy       | D’Almeida 1992| 9 / 50         | 0.69       | 0.33        | 1.47        | 0.039    | 0.66            |                |
|                           | Buhorna 1994  | 12 / 32        | 1.66       | 0.75        | 3.06        | 0.209    | 6.0             |                |
|                           | Osowide 1995  | 38 / 113       | 1.34       | 0.78        | 1.67        | 0.490    | 25.8            |                |
|                           | Olsen 2000 a  | 35 / 167       | 0.99       | 0.73        | 1.33        | 0.597    | 42.0            |                |
|                           | Olsen 2000 b  | 38 / 274       | 1.33       | 0.85        | 2.10        | 0.213    | 18.1            |                |
|                           | Kuper 2017 b  | 5 / 64         | 2.81       | 0.57        | 14.00       | 0.207    | 1.4             |                |
| Subtotal                  | 157 / 760     | 147 / 34       | 1.11       | 0.91        | 1.34        | 0.296    |                |                |
| Low risk pregnancy        | Olsen 1990    | 511 / 2510     | 0.96       | 0.86        | 1.07        | 0.428    | 82.8            |                |
|                           | Selvig 1996   | 8 / 266        | 1.15       | 0.42        | 3.12        | 0.708    | 1.0             |                |
|                           | Zhou 2012     | 98 / 1197      | 0.92       | 0.71        | 1.20        | 0.531    | 14.0            |                |
|                           | Kuper 2017 a  | 15 / 370       | 0.78       | 0.40        | 1.52        | 0.460    | 2.2             |                |
| Subtotal                  | 622 / 4343    | 666 / 4225     | 0.95       | 0.86        | 1.05        | 0.299    |                |                |
| Overall                   | 785 / 5043    | 815 / 5659     | 0.98       | 0.90        | 1.07        | 0.652    |                |                |

High risk: Heterogeneity: Ch2 = 5.03, df = 5 (P = 0.612); I2 = 67%, Test for overall effect: Z = 1.65 (P = 0.096)

Low risk: Heterogeneity: Ch2 = 9.56, df = 3 (P = 0.039); I2 = 0%, Test for overall effect: Z = 1.038 (P = 0.00299)

Overall: Heterogeneity: Ch2 = 7.56, df = 9 (P = 0.579); I2 = 0%, Test for overall effect: Z = 0.531 (P = 0.602)

Fig-6:

Meta-analysis results showing the effectiveness of omega-3 supplementation in reducing hypertension.
PUFAs have been shown to induce the formation of nitric oxide, which prevents vasoconstriction [44]. A 6:1 ratio mixture of EPA: DHA was provided to Wister rats. Examined whether chronic intake of induces the function of angiotensin II in rats [45]. The results revealed that the consumption of chronic EPA: DHA ratios prevented Ang-II induced hypertension as well as endothelial dysfunction by limiting the activity of COX-derived oxidative and NADPH oxidase stress. The results have been indicated in (Fig-7).

**EPA and DHA reduce hypertension by altering various hemodynamic.** For instance, the use of o0f EPA and DHA has various effects on blood pressure, heart rates, cardiac diastolic filling, and arterial compliance, as summarised in the information provided in **(Table-2)**.

**Impact of ω-3 and ω-6 PUFAs in Thrombogenesis:**

Polyunsaturated fatty acids have been shown to exhibit antithrombotic properties [47]. Available studies indicate that the Eskimo diet that is rich in intake of seafood contains high levels polyunsaturated fatty acids which have been directly linked with low incidences of cardiovascular diseases as well as a decrease in thrombogenesis [48,49]. Most of the above effects have been described in populations found in different areas although the inverse relationship between intake of omega-3 polyunsaturated fatty acids has been associated with platelet aggregation, fibrinolysis, and coagulation has not been completely elucidated [50]. Nonetheless, in-vitro and in vivo studies reveal that the use of polyunsaturated fatty acids supplementation reduces the synthesis of thromboxane 2, platelet adhesion and activation and decreases the concentration and activity of plasminogen activator inhibitor-1 [16,51]. The specific mechanism in which omega-3 polyunsaturated fatty acids decrease levels of thrombogenesis has been studied, especially in platelets.

High levels of common polyunsaturated fatty acids, such as EPA and DHA, favor the replacement of arachidonic acid within the phospholipids of the cell membrane [52]. This decreases the binding of arachidonic acid on cyclooxygenase 1, reducing the synthesis of thromboxane A2, which is considered as an element that increases platelet aggregation and vasoconstriction [52,53]. The approach also produces Thromboxane A3, which exerts a low biological effect compared to thromboxane A2. Another suggested mechanism in which omega-3 polyunsaturated fatty acids reduces thrombogenesis involves the synthesis of protectin DX which is considered a product of dihydroxylation of DHA [54,55]. The product inhibits the activity of cyclooxygenase 1 and cyclooxygenase 2 in neutrophils and platelets, reducing platelet aggregation and activation, as indicated in (Fig-8).

DHA and EPA were reported to have minimal effects on thrombosis or coagulation. Furthermore, the use of DHA and EPA are indicated to reduce inflammation and oxidative stress, which have been linked with thrombogenesis. The results are indicated in **(Table-3)**.

---

**Review Article**

---

**Table-2: Effect of EPA and DHA on blood pressure variables [46]**

|                | EPA                                      | DHA                                      |
|----------------|------------------------------------------|------------------------------------------|
| Cardiac hemodynamics | Has minimal effects on blood pressure | Reduces blood pressure level            |
|                 | Reduces heart rate                     | Reduces heart rate                      |
|                 | Promotes cardiac diastolic filling     | Promotes cardiac diastolic filling      |
|                 | Promotes arterial compliance           | Promotes arterial compliance             |

---

**Fig-7:**

Chronic intake of PUFAs prevents Angiotensin-II hypertension in rats in the first week when fed orally before the level rises when rats are fed using a somatic pump. The results adapted from [45].

---

**Fig-8:**

High levels of common polyunsaturated fatty acids, such as EPA and DHA, favor the replacement of arachidonic acid within the phospholipids of the cell membrane [52]. This decreases the binding of arachidonic acid on cyclooxygenase 1, reducing the synthesis of thromboxane A2, which is considered as an element that increases platelet aggregation and vasoconstriction [52,53]. The approach also produces Thromboxane A3, which exerts a low biological effect compared to thromboxane A2. Another suggested mechanism in which omega-3 polyunsaturated fatty acids reduces thrombogenesis involves the synthesis of protectin DX which is considered a product of dihydroxylation of DHA [54,55]. The product inhibits the activity of cyclooxygenase 1 and cyclooxygenase 2 in neutrophils and platelets, reducing platelet aggregation and activation, as indicated in (Fig-8).
Human beings associated thromboembolism with endothelial function [56]. Previous studies have already reported on the improved effect of EPA and DHA on the endothelial function of arteries, but the impact on veins is largely unclear [57,58]. [60] report that administration of EPA: DHA in a ration of 6:1 for a week resulted in the release of acetylcholine, which causes relaxation of veins at low concentrations. Also EPA: DHA ratios of 1:1 increased acetylcholine levels resulting in the relaxation of femoral vein. Corn oil did not show any difference (Fig-9).

**Impact of ω-3 and ω-6 on Lipid Profiles:**

Maintaining and monitoring healthy levels of lipids circulating within the bloodstream remains one of the essential methods used to diagnose different cardiovascular diseases [47]. A lipid panel or profile is considered as a group of individual tests that evaluate an individual risk of developing different cardiovascular treatments [60]. Normally, lipid profiles consist of various types of molecules, including total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides [61]. HDL is regarded as the good cholesterol and removes excess cholesterol from arteries and also carries low-density lipoproteins cholesterol back to the liver for decomposition and removal from the body [62,63]. The application of diets rich in either omega-6 or omega 3 fats significantly improves cardiovascular health by directly improving the activity of HDL and lowering levels of LDLs. [64] observed that a diet rich in omega-3 supplementation greatly improved lipid metabolism, reduced triglycerides levels, and increased activity of HDLs as well as anti-platelet activity and anti-inflammatory effects. Similarly, a systematic review and meta-analysis by [1] observed that consumption of polyunsaturated fatty acids was associated with a

| Table-3: EPA and DHA effect on thrombogenesis related factors [46] |
|---------------------------------------------------------------|
| Thrombosis and coagulation                                   |
| EPA              | DHA              |
| ↓ Collagen-stimulated platelet aggregation       | ↓ Collagen-stimulated platelet aggregation       |
| Otherwise minimal effects on thrombosis or coagulation     | Otherwise minimal effects on thrombosis or coagulation |
| Endothelial function                                      |
| Reduces inflammation                                      | Reduces inflammation                              |
| Reduces oxidative stress                                   | Reduces oxidative stress                          |

**Fig-8:**

Role of polyunsaturated fatty acids in thrombogenesis. The first mechanism involves reducing the synthesis of thromboxane A2 and the effect of protectin DX [39].
decrease in low-density lipoprotein and an increase in high-density lipoprotein which is associated with reduced incidences of coronary heart diseases.

Although there is less recent randomized clinical trials evidence examining the effects of dietary fats on various outcomes, a large body examining the impact of dietary fat on lipid profiles has been reported. A higher level of atherogenic cholesterol or cholesterol carried in non-HDL vesicles, and LDL has been implicated in atherosclerosis [65]. Corn olive oil has been shown to reduce LDL and the total cholesterol level [66]. However, the study by [8] reported no significant effects while comparing the effects on blood lipid after consumption PUFAs, although the study was dominated by findings of one paper. A systematic review by [67] also reported that the use of canola oil reduces low-density lipoprotein but had no effect on high-density lipoproteins. Guidelines in managing the condition are associated with reducing the concentrations of LDL cholesterol. The replacement of saturated fatty acids (SFA) with PUFAs lowers cholesterol LDL and changes the triglycerides: HDL cholesterol level as shown in (Table-4).

![Fig-9:](Effect of EPA: DHA ratios of 6:1 and 1:1 on veins. Acetylcholine levels reduce, resulting in the relaxation of veins [59].)

| Table-4: Changes in total cholesterol (Total-C), LDL Cholesterol, HDL cholesterol, Total-C/HDL cholesterol and TGs when diets are changed from SFA to carbohydrates (CHO), SFAs to Monounsaturated fatty acid (MUFA) and SFA to PUFAs [68] |
|-----------------|-----------------|-----------------|-----------------|
| Lipoprotein lipid | SFAs → CHO | SFAs → MUFA | SFAs → PUFAs |
| Total-C | $-0.041 (-0.047, -0.035)$ | $-0.046 (-0.051, -0.040)$ | $-0.064 (-0.070, -0.058)$ |
| LDL cholesterol | $-0.033 (-0.039, -0.027)$ | $-0.042 (-0.047, -0.037)$ | $-0.055 (-0.061, -0.050)$ |
| HDL cholesterol | $-0.010 (-0.012, -0.008)$ | $-0.002 (-0.004, 0.000)$ | $-0.005 (-0.006, -0.003)$ |
| Total-C/HDL cholesterol | $0.001 (-0.006, 0.007)$ | $-0.027 (-0.033, -0.022)$ | $-0.034 (-0.040, -0.028)$ |
| TGs | $0.011 (0.007, 0.014)$ | $-0.004 (-0.007, -0.001)$ | $-0.010 (-0.014, -0.007)$ |
ApoA-I is regarded as the main protein component present in HDL particles, which promotes the maturation of HDL by allowing cholesterol efflux from various cells [69]. It also stimulates cholesterol esterification through the activity of the enzyme lecithin cholesterol acyltransferase (LCAT) [70]. Plasma levels of LCAT increase with the consumption of highly enriched omega-3 oil [17]. Consumption of omega-3 increases the hepatic and plasma expression of ApoA-I and is linked with the anti-oxidative activity of HDLs. ApoA-I stabilises the activity of paraoxonase-1 (PON1) which is linked to HDL [71]. PON1 reduces the oxidative stress associated with macrophages, reduces the production of proinflammatory cytokines [72], and increases cholesterol efflux capacity of macrophages [73], as shown in (Fig-10).

The study by [75] reported that lipoprotein apheresis could be used in managing atherosclerosis. Lipoprotein apheresis decreases levels of essential omega 3 and omega 3 PUFAs in blood plasma, but the use of heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) is associated with proinflammatory activity of omega-3 and -6 PUFAs. HELP-treated patients showed cardioprotective effects and limited inflammatory reaction HDL levels increasing and a reduction being observed in HDL and no significant differences being observed in LDL, cholesterol, and triglycerides, as shown in (Fig-11). The result recommending omega-3 supplementation in lipid apheresis could have additional benefits.

The blow (Table-5) summaries the effect of PUFAs on cardiometabolic health.

Further analysis reveals that the use of EPA and DHA is linked to a reduction in cardiovascular outcomes, as indicated by the relative risks across various studies indicated below (Table-6). Individuals who did not take EPA and DHA had higher relative risks of developing coronary heart diseases as compared to those using PUFA [76]. High levels of triglycerides and lipoproteins were also observed among those who did not take PUFA.
Fig-11: HELP-treated patients showing differences in lipid profiles [75].

Table-5: The action of PUFA on cardiometabolic health summary [72]

|                      | Omega 3                                                                 | Omega 6                                                                 |
|----------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
| **Cholesterol**      | EPA and DHA reduces levels of Low-density lipoproteins (LDL) and increases levels of High-Density Lipoproteins (HDL) | Less scientific data on the effect of omega 6 on HDL and LDL levels       |
| **Thrombogenesis**   | Formation of protecin DX which limits the activity of cyclooxygenase 1 and 2 | Inhibiting the synthesis of thromboxane A2, which affects the production of arachidonic acid, decreasing the activity of cyclooxygenase 1. |
| **Inflammation**     | Activation and binding of Beta-arrestin-2, which breaks down to produce TABI, which inhibits TAKI and disrupting the remaining pathways. The presence of DHA and EPA interferes with the translocation of TLR-4, which serves to inhibit the production of cytokines. | Dietary linoleic acid increase s activity of cyclooxygenase 2 which increases the conversion of arachidonic acid to proinflammatory eicosanoid in the process reducing the concentration of arachidonic acid |
| **Blood pressure and hypertension** | Conversion of prostaglandins to arachidonic acid and subsequent release of vasodilators like nitric oxide. | Inhibition of ACE and the role of cytochrome p450 in activating nitric oxide |
Table-6: A meta-analysis table – table constructed to highlight the main contents of this literature review based on thorough analysis of all the primary research, studies and data involved

| Author | Title | Relevance to the topic |
|--------|-------|------------------------|
| [7]    | Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials. | [7] established elevated LDL-cholesterol as atherosclerosis and CVD risk factor. The research that they conducted demonstrated that increased ω-3 and ω-6 intake had hypocholesterolaemia effects. However, the information provided in their study concerning the specific effects of ω-6 PUFA on blood lipid profiles is limited. |
| [1]    | Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease | Most of the RCT data used by [1] in his study to determine the effects of PUFAs on cardiometabolic diseases was quite old. From his findings, replacement of 5% SFAs by PUFAs significantly reduced CAD risks. |
| [6]    | Overweight, obesity, and risk of cardiometabolic multimorbidity | [6] in their work, conducted a Cochrane meta-analysis where they examined SFA intake reduction and replacing it with PUFA or MUFA. Their research concluded that replacement of SFAs with ω-3 and ω-6 PUFAs resulted in a 17% reduction in cardiometabolic events. They reported that, replacing some saturated fats with PUFAs having plants origin resulted yielded lower cardiometabolic disease risk. Subgroup analysis conducted showed lower risks in PUFA compared to SFA groups. |
| [11]   | Biochemical mechanism of the ratio of omega 6 to 3 fatty acids on blood lipid reduction | [11] literature is relevant to this study, where they conducted a crosssectional analysis of Spanish men considered obese. The men underwent laparoscopic gastric bypass surgery. Analysis of the abdominal adipose tissue and venous blood serum was conducted to calculate FA composition. A positive correlation of ω-6 PUFAs with HDL-C and an inverse correlation with triglycerides (TG) was found. |
| [13]   | The ratio of dietary ω-3 and ω-6 fatty acids independent determinants of muscle mass in hemodialysis patients with diabetes. | [13] conducted observational studies among the East Asian and Asian Indian population, which is relevant to this study. They found out through research that, omega 6 PUFAs to be inversely associated with TG across the population studied. A cross-sectional analysis conducted on male cohort found serum LA to be positively associated with HDL-C particle size and inversely associated with LDL-C and VLDL particle sizes. |
| [15]   | A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease | [15] carried out a meta-analysis of 80 controlled interventional trials where they concluded that n-6 PUFA has beneficial effects on blood lipid levels. The total PUFAs can be considered to be equal to omega 6 PUFA with a number of 18 carbons. |
| [22]   | Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. | Their research associated a reduction in blood pressure with a reduction in CVD risks. They concluded in their research that dietary LA is inversely associated with blood pressure (BP) |
| [29]   | The associations of serum n-6 polyunsaturated fatty acids with serum C-reactive protein in men: The Kuopio Ischaemic Heart Disease Risk Factor Study | Cardiometabolic conditions are directly attributed to modifiable behaviors such as sedentary activity and poor diet. Omega 3 (C20:5 ω 3) polyunsaturated fatty acids have pleotropic effects on the functioning of cells, control inflammatory factors and cellular events in vascular endothelial cells and cardiomyocytes. The hypolipemic, anti-arrhythmic, and anti-inflammatory properties of fatty acids offer cardioprotection. |
Conclusion
Cardiometabolic diseases are significant health and economic burden globally since they contribute to preventable mortality and morbidity in individuals of all ages, races, and genders. One of the most effective approaches towards the prevention and management of cardiometabolic diseases include lifestyle and dietary changes. Based on the meta-analysis, ω-3 and ω-6 PUFAs are essential fatty acids in the body functioning, and since they are not synthesized in the human body, they are mostly consumed through the dietary sources and nutritional supplements. The significance of ω-3 PUFAs on cardiometabolic is clear that is the reduction of inflammation agents that may contribute to metabolic syndrome as well as being essential in the prevention of cardiovascular diseases like thrombosis. Similarly, ω-6 PUFAs are important in the promotion of cardiovascular health by lowering cholesterol levels. Despite the highlighted benefits of the two fatty acids on cardiometabolic health, a significant controversy relates to the question as to whether ω-6 PUFAs contribute to inflammation or not. For instance, the conversion of SFA to PUFAs is always associated with a brisk of increasing inflammation. Omega 3- and 6 fatty acids have also been indicated to compete for substrates, and as a result, omega-3 is linked with anti-inflammatory behavior while omega-6 is linked with proinflammatory behavior. Also, the formation of omega-6 fatty acids is associated with the release of inflammatory molecules such as leukotrienes. The effect of downstream products produced by omega-3 and omega-6 fatty acids in relation to inflammation also remains unknown, while other studies suggest that inflammation linked to omega-6 could be explained by the highomega-3 to omega 6 ratios. Thus, there is a need to carry out more research on the link between omega-6 PUFAs and inflammation with specific emphasis being placed on the exact mechanism.

References
[1] Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, Song F, Hooper L. Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD012345. [PMID: 30019767]
[2] Forouhi NG, Krauss RM, Taubes G, Willett W. Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance. BMJ. 2018 Jun 13;361:k2139. [PMID: 29898882]
[3] Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018 Jan;61(1):21-28. [PMID: 28776083]
[4] Vincent GE, Jay SM, Sargent C, Vandelanotte C, Ridgers ND, Ferguson SA. Improving Cardiometabolic Health with Diet, Physical Activity, and Breaking Up Sitting: What about Sleep? Front Physiol. 2017 Nov 8;8:865. [PMID: 29167645]
[5] Van Elten TM, Van Poppel MNM, Gemke RBJ, Groen H, Hoek A, Mol BW, Roseboom TJ. Cardiometabolic Health in Relation to Lifestyle and Body Weight Changes 3-8 Years Earlier. Nutrients. 2018 Dec 10;10(12):1953. [PMID: 30544716]
[6] Kivimäki M, Kuosma E, Ferrie JE, Luukkonen R, Nyberg ST, Alfredsson L, Batty GD, Brunner EJ, Fransson E, Goldberg M, Knutsson A, Koskenuvu M, Nordin M, Oksanen T, Pentti J, Rugulies R, Shipley MJ, Singh-Manoux A, Steptoe A, Suominen SB, Theorell T, Vahtera J, Virtanen M, Westerholm P, Westerlund H, Zins M, Hamer M, Bell JA, Tabak AG, Jokela M. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017 May 19;2(6):e277-e285. [PMID: 28626830]
[7] Brown TJ, Brainard J, Song F, Wang X, Abdelhamid A, Hooper L; PUFAH Group. Omega-3, omega-6, and total dietary polyunsaturated fat for prevention and treatment of type 2 diabetes mellitus: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019 Aug 21;366:l4697. [PMID: 31434641]
[8] Al-Khudairy L, Hartley L, Clar C, Flowers N, Hooper L, Rees K. Omega 6 fatty acids for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2015 Nov 16;(11):CD011094. [PMID: 26571451]
[9] Crowe-White KM, Cardel MI, Burkhalter HH, Huo T, Fernández JR. Higher n-6:n-3 Fatty Acid Intake Is Associated with Decreased Cardiometabolic Risk Factors in a Racially Diverse Sample of Children. Curr Dev Nutr. 2018 Apr 3;2(5):nzy014. [PMID: 29955726]
[10] Johnson M. Diet and Nutrition: Implications for
Cardiometabolic Health. Journal of Cardiology and Cardiovascular Sciences. (2019);3(2):4-9.

[11] Lee SH, Kim JS, Choi DH, Kim CR, Um KH, Park BS. Biochemical mechanism of the ratio of omega 6 to 3 fatty acid on blood lipid reduction in rats. Journal of the Korean Applied Science and Technology. 2017;34(2):315-26.

[12] Ricci G, Canducci E, Guida A, Arena R, Ambra F, Ravani B, Alvisi V. Effects of Unbalanced Polynsaturated Fatty Acid Intake on Obesity-related Metabolic and Hepatic Dysfunctions. Modern Clinical Medicine Research. 2017;1(2).

[13] Wong TC, Chen YT, Wu PY, Chen TW, Chen HH, Chen TH, Hsu YH, Yang SH. Ratio of dietary ω-3 and ω-6 fatty acids-independent determinants of muscle mass-in hemodialysis patients with diabetes. Nutrition. 2016 Sep;32(9):989-94. [PMID: 27157471]

[14] Maki KC, Eren F, Cassens ME, Dicklin MR, Davidson MH. ω-6 Polysaturated Fatty Acids and Cardiometabolic Health: Current Evidence, Controversies, and Research Gaps. Adv Nutr. 2018 Nov 1;9(6):688-700. [PMID: 30184091]

[15] Clifton PM, Keogh JB. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. Nutr Metab Cardiovasc Dis. 2017 Dec;27(12):1060-80. [PMID: 29174025]

[16] Adli R, Hawley M, Holinstat M. Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids. Prostaglandins Other Lipid Mediat. 2018 Nov;139:10-18. [PMID: 30266534]

[17] Elshourbagy NA, Meyers HV, Abdel-Meguid SS. Cholesterol: the good, the bad, and the ugly - therapeutic targets for the treatment of dyslipidemia. Med Princ Pract. 2014;23(2):99-111. [PMID: 24334831]

[18] Donath MY, Meier DT, Böni-Schnetzler M. Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease. Endocr Rev. 2019 Aug 1;40(4):1080-91. [PMID: 31127805]

[19] Deng FE, Shivappa N, Tang Y, Mann JR, Hebert JR. Association between diet-related inflammation, all-cause, all-cancer, and cardiovascular disease mortality, with special focus on prediabetics: findings from NHANES III. Eur J Nutr. 2017 Apr;56(3):1085-93. [PMID: 26825592]

[20] Ely BR, Clayton ZS, McCurdy CE, Pfeiffer J, Minson CT. Meta-inflammation and cardiometabolic disease in obesity: Can heat therapy help? Temperature (Austin). 2017 Nov 10;5(1):9-21. [PMID: 29687041]

[21] Gambardella J, Santulli G. Integrating diet and inflammation to calculate cardiovascular risk. Atherosclerosis. 2016 Oct;253:258-61. [PMID: 27594541]

[22] Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empapa JP, Etgen T, Franco OH, Igliseder B, Johnsen SH, Kavoussi M, Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagiannì A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Ikrmt MA, Völzke H, Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLaughlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; PROG-IMT study group. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol. 2016 Jan;23(2):194-205. [PMID: 25416041]

[23] Illich JZ, Kelly OJ, Kim Y, Spicer MT. Low-grade chronic inflammation perpetuated by modern diet as a promoter of obesity and osteoporosis. Arth Rada Toksikol. 2014 Jun;65(2):139-48. [PMID: 24945146]

[24] Molfino A, Amabile MI, Monti M, Muscaritoli M. Omega-3 Polynsaturated Fatty Acids in Critical Illness: Anti-Inflammatory, Proresolving, or Both? Oxid Med Cell Longev. 2017;2017:5987082. [PMID: 28694914]

[25] Jang H, Park K. Omega-3 and omega-6 polyunsaturated fatty acids and metabolic syndrome: A systematic review and meta-analysis. Clin Nutr. 2020 Mar;39(3):765-73. [PMID: 31017071]

[26] Innes JK, Calder PC. Omega-6 fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2018 May;132:111. [PMID: 29610056]

[27] Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions. 2017 Oct 15;45(5):1105-15.

[28] Esser N, Paquot N, Scheen AJ. Inflammatory markers and cardiometabolic diseases. Acta Clin Belg. 2015 Jun;70(3):193-99. [PMID: 26103387]

[29] Virtanen JK, Mursu J, Voutilainen S, Tuomainen
TP. The associations of serum n-6 polyunsaturated fatty acids with serum C-reactive protein in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Eur J Clin Nutr. 2018 Mar;72(3):342-48. [PMID: 29851239]
[30] Tortosa-Caparrós E, Navas-Carrillo D, Marin F, Orenes-Piñero E. Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. Crit Rev Food Sci Nutr. 2017 Nov 2;57(16):3421-29. [PMID: 26745681]
[31] Marchix J, Choque B, Koubá M, Fautrel A, Catheline D, Legrand P. Excessive dietary linoleic acid induces proinflammatory markers in rats. J Nutr Biochem. 2015 Dec;26(12):1434-41. [PMID: 26337666]
[32] Simopoulos AP. An Increase in the Omega-6/Omega-3 Fatty Acid Ratio Increases the Risk for Obesity. Nutrients. 2016 Mar 2;8(3):128. [PMID: 26950145]
[33] Pan A, Chen M, Chowdhury R, Wu JH, Sun Q, Campos H, Mozaffarian D, Hu FB. α-Linolenic acid and risk of cardiovascular disease: a systematic review and meta-analysis. Am J Clin Nutr. 2012 Dec;96(6):1262-73. [PMID: 23076616]
[34] Calder PC. Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids. 2015 Apr 1;1851(4):469-84.
[35] Robertson RC, Guihéneuf F, Bahar B, Schmid M, Stengel DB, Fitzgerald GF, Ross RP, Stanton C. The Anti-Inflammatory Effect of Algae-Derived Lipid Extracts on Lipopolysaccharide (LPS)-Stimulated Human THP-1 Macrophages. Mar Drugs. 2015 Aug 20;13(8):5402-24. [PMID: 26308008]
[36] Inoue T, Tanaka M, Masuda S, Ohue-Kitano R, Yamakage H, Muranaka K, Wada H, Kusakabe T, Shimatsu A, Hasegawa K, Satoh-Asahara N. Omega-3 polyunsaturated fatty acids suppress the inflammatory responses of lipopolysaccharide-stimulated mouse microglia by activating SIRT1 pathways. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 May;1862(5):552-60. [PMID: 28254441]
[37] Sakai C, Ishida M, Ohba H, Yamashita H, Uchida H, Yoshizumi M, Ishida T. Fish oil omega-3 polyunsaturated fatty acids attenuate oxidative stress-induced DNA damage in vascular endothelial cells. PLoS One. 2017 Nov 9;12(11):e0187934. [PMID: 29121093]
[38] Honda KL, Lamon-Fava S, Matthan NR, Wu D, Lichtenstein AH. EPA and DHA exposure alters the inflammatory response but not the surface expression of Toll-like receptor 4 in macrophages. Lipids. 2015 Feb;50(2):121-29. [PMID: 25408476]
[39] Saini RK, Keum YS. Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance - A review. Life Sci. 2018 Jun 15;203:255-67. [PMID: 29715470]
[40] Shahidi F, Ambigaipalan P. Omega-3 Polyunsaturated Fatty Acids and Their Health Benefits. Annu Rev Food Sci Technol. 2018 Mar 25;9:345-81. [PMID: 29330557]
[41] Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19(3):441-45. [PMID: 25720716]
[42] Krautz MJ, Havranek EP, Pereira RI, Beaty B, Meehler PS, Long CS. Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study. J Negat Results Biomed. 2015 Dec 2;14:21. [PMID: 26631058]
[43] Bakouei F, Delavar MA, Mashayekh-Amiri S, Esmaillzadeh S, Taheri Z. Efficacy of n-3 fatty acids supplementation on the prevention of pregnancy induced-hypertension or preeclampsia: A systematic review and meta-analysis. Taiwanese Journal of Obstetrics and Gynecology. 2020 Jan 1;59(1):8-15.
[44] Te Riet I, van Esch JH, Roos AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015 Mar 13;116(6):960-75. [PMID: 25762833]
[45] Niazi ZR, Silva GC, Ribeiro TP, León-González AJ, Kassem M, Mirajkar A, Alvi A, Abbas M, Zghel F, Schini-Kerth VB, Auger C. EPA:DHA 6:1 prevents angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase- and COX-derived oxidative stress. Hypertens Res. 2017 Dec;40(12):966-75. [PMID: 28878301]
[46] Yamagata K. Docosahexaenoic acid regulates vascular endothelial cell function and prevents cardiovascular disease. Lipids Health Dis. 2017 Jun 15;16(1):118. [PMID: 28619112]
[47] Sokola-Wysoczanska E, Wysoczanski T, Wagner J, Czyż K, Bodkowski R, Lochyński S, Patkowska-Sokola B. Polyunsaturated Fatty Acids and Their Potential Therapeutic Role in Cardiovascular System Disorders.
A Review. Nutrients. 2018 Oct 21;10(10):1561. [PMID: 30347877]

[48] De Souza RJ, Mente A, MaroLEANu A, Cozma AI, Ha V, Kishibe T, Uleryk E, BudyloWski P, Schünemann H, Beyene J, Anand SS. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. Bmj. 2015 Aug 12;351:h3978.

[49] Rimm EB, Appel LJ, ChiueE SE, Djoussé L, Engler MB, Kris-Etherton PM, Mozaffarian D, Siscovick DS, Lichtenstein AH; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Seafood Long-Chain n-3 Polyunsaturated Fatty Acids and Cardiovascular Disease: A Science Advisory From the American Heart Association. Circulation. 2018 Jul 3;138(1):e35-e47. [PMID: 29773586]

[50] Stupin M, Kibel A, Stupin A, Selthofer-Relatić K, Matić A, Mihalj M, Mihaljević Z, Jukić I, Drenjančević I. The Physiological Effect of n-3 Polyunsaturated Fatty Acids (n-3 PUFA) Intake and Exercise on Hemorheology, Microvascular Function, and Physical Performance in Health and Cardiovascular Diseases: Is There an Interaction of Exercise and Dietary n-3 PUFA Intake? Front Physiol. 2019 Aug 30;10:1129. [PMID: 31543828]

[51] Thota RN, Ferguson JJA, Abbott KA, Dias CB, Garg ML. Science behind the cardio-metabolic benefits of omega-3 polyunsaturated fatty acids: biochemical effects vs. clinical outcomes. Food Funct. 2018 Jul 17;9(7):3576-96. [PMID: 29904777]

[52] Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015 Apr 21;7:52. [PMID: 25954194]

[53] Drouin G, Rioux V, Legrand P. The n-3 docosapentaenoic acid (DPA): A new player in the n-3 long chain polyunsaturated fatty acid family. Biochimie. 2019 Apr;159:36-48. [PMID: 30716358]

[54] Schwanke RC, Marcon R, Bento AF, Calixto JB. EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease. Eur J Pharmacol. 2016 Aug 15;785:156-64. [PMID: 26325092]

[55] Zárate R, El Jaber-Vazdeks N, Tejera N, Pérez JA, Rodríguez C. Significance of long chain polyunsaturated fatty acids in human health. Clin Transl Med. 2017 Dec;6(1):25. [PMID: 28753333]

[56] ByrneS JR, Wolberg AS. New findings on venous thrombogenesis. Hamostaseologie. 2017 Jan 31;37(1):25-35. [PMID: 27878206]

[57] Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin. Biomed Pharmacother. 2018 Jul;103:1231-37. [PMID: 29864903]

[58] Yagi S, Aihara K, Fukuda D, Takashima A, Hara T, Hotchi J, Ise T, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M, Sata M. Effects of docosahexaenoic Acid on the endothelial function in patients with coronary artery disease. J Atheroscler Thromb. 2015;22(5):447-54. [PMID: 25342567]

[59] Gaertner S, Auger C, Farooq MA, Pollet B, Khemais-Benkhiat S, Niazi ZR, Schrevens S, Park SH, Toti F, Stephan D, Schini-Kerth VB. Oral Intake of EPA:DHA 6:1 by Middle-Aged Rats for One Week Improves Age-Related Endothelial Dysfunction in Both the Femoral Artery and Vein: Role of Cyclooxygenases. Int J Mol Sci. 2020 Jan 30;21(3):920. [PMID: 32019237]

[60] Marventano S, Kolacz P, Castellano S, Galvano F, Buscemi S, Mistretta A, Grosso G. A review of recent evidence in human studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders: does the ratio really matter? Int J Food Sci Nutr. 2015;66(6):611-22. [PMID: 26307560]

[61] Schroeder EA, Brunet A. Lipid Profiles and Signals for Long Life. Trends Endocrinol Metab. 2015 Nov;26(11):589-92. [PMID: 26439976]

[62] Bergeheau SC, Bodde MC, Jukema JW. Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment. Neth Heart J. 2017 Apr;25(4):231-42. [PMID: 28194698]

[63] Wang F, Zheng J, Yang B, Jiang J, Fu Y, Li D. Effects of Vegetarian Diets on Blood Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2015 Oct 27;4(10):e002408. [PMID: 26508743]
Keywords: Omega-3, Omega-6, Polyunsaturated fatty acids, Cardiometabolic health

Citation: Halim M, Halim A. Omega 3 versus Omega 6 Polyunsaturated Fatty Acids in Cardio-Metabolic Health. J Health Care and Research. 2020 Jun 27;1(2):83-100.

Review Article

[64] Yanai H, Masui Y, Katsuyama H, Adachi H, Kawaguchi A, Hakoshima M, Waragai Y, Harigae T, Sako A. An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids. J Clin Med Res. 2018 Apr;10(4):281-89. [PMID: 29511415]

[65] Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1. J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-S22.e1. [PMID: 26724525]

[66] Maki KC, Lawless AL, Kelley KM, Kaden VN, Geiger CJ, Palacios OM, Dicklin MR. Corn oil intake favorably impacts lipoprotein cholesterol, apolipoprotein and lipoprotein particle levels compared with extra-virgin olive oil. Eur J Clin Nutr. 2017 Jan;71(1):33-38. [PMID: 27677368]

[67] Lin L, Allemekinders H, Danshy A, Campbell L, Durance-Tod S, Berger A, Jones PJ. Evidence of health benefits of canola oil. Nutr Rev. 2013 Jun;71(6):370-385. [PMID: 23731447]

[68] Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. World Health Organization; 2016:1-63. Available from: https://apps.who.int/iris/bitstream/handle/10665/246104/9789241565349-eng.pdf

[69] Gugliucci A, Menini T. Paraoxonase 1 and HDL maturation. Clin Chim Acta. 2015 Jan 15;439:5-13. [PMID: 25261854]

[70] Saedi R, Li M, Frohlich J. A review on lecithin:cholesterol acyltransferase deficiency. Clin Biochem. 2015 May;48(7-8):472-75. [PMID: 25172171]

[71] Takaeidi MR, Jahangiri A, Khodayar MJ, Siahpoosh A, Yaghooti H, Rezaei S, Salecheh M, Mansourzadeh Z. The Effect of Date Seed (Phoenix dactylifera) Extract on Paraoxonase and Arylesterase Activities in Hypercholesterolemic Rats. Jundishapur J Nat Pharm Prod. 2014 Feb;9(1):30-34. [PMID: 24844436]

[72] Kunutsor SK, Bakker SJ, James RW, Dullaart RP. Serum paraoxonase-1 activity and risk of incident cardiovascular disease: The PREVEND study and meta-analysis of prospective population studies. Atherosclerosis. 2016 Feb;245:143-54. [PMID: 26724525]

[73] Chernyavskiy I, Veeranki S, Sen U, Tyagi SC. Atherogenesis: hyperhomocysteinemia interactions with LDL, macrophage function, paraoxonase 1, and exercise. Ann N Y Acad Sci. 2016 Jan;1363(1):138-54. [PMID: 26849408]

[74] Pizzini A, Lunger L, Demetz E, Hilbe R, Weiss G, Ebenbichler C, Tancevski I. The Role of Omega-3 Fatty Acids in Reverse Cholesterol Transport: A Review. Nutrients. 2017 Oct 6;9(10):1099. [PMID: 28984832]

[75] Weylandt KH, Schmöcker C, Ostermann AI, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willenberg I, Willen